Charles A. Sammons Cancer Center/Texas Oncology Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2015
NCT02548169
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Charles A. Sammons Cancer Center/Texas Oncology

Active Ingredients

Drugs in Phase 2 Trials (1)

anakinra (Kineret) (1 trial)

Drugs in Phase 1 Trials (1)

tumor-pulsed dendritic cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pancreatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2